Market Place
Sourcing Support
Supernus Pharma to Attend 2024 Jefferies London Healthcare
13 Nov 2024 //
GLOBENEWSWIRE
Supernus Announces Q3 2024 Financial Results
04 Nov 2024 //
GLOBENEWSWIRE
Supernus Presents Ph 2a SPN-820 in Depression at Psych Congress
31 Oct 2024 //
GLOBENEWSWIRE
Supernus Pharma Hosts Call On November 4 For Q3 Financial Results
21 Oct 2024 //
GLOBENEWSWIRE
Supernus links depression drug to fast responses in ph. 2 trial
18 Oct 2024 //
FIERCE BIOTECH
Supernus Shares Data From Phase 2a Study Of SPN-820 For Depression
17 Oct 2024 //
GLOBENEWSWIRE
Supernus Hosts Webcast On Ph 2 study For Major Depressive Disorder
10 Oct 2024 //
GLOBENEWSWIRE
Busy Philipps Supports Women’s ADHD Awareness with Supernus
24 Sep 2024 //
GLOBENEWSWIRE
Supernus To Participate In TD Cowen Neuropsychiatry Summit
19 Sep 2024 //
GLOBENEWSWIRE
Supernus Pharmaceuticals To Attend Wells Fargo Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Supernus` SPN-830 Apomorphine Infusion Device NDA Accepted By FDA
19 Aug 2024 //
GLOBENEWSWIRE
Supernus Announces Second Quarter 2024 Financial Results
06 Aug 2024 //
GLOBENEWSWIRE
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01 Aug 2024 //
GLOBENEWSWIRE
Supernus To Announce Q2 2024 Results On August 6
23 Jul 2024 //
GLOBENEWSWIRE
Supernus At Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Supernus Spn-817 Interim Promising: Open-Label Phase 2a Epilepsy Data
23 May 2024 //
GLOBENEWSWIRE
Supernus Webcast On SPN-817 Open-Label Seizure Study Data
09 May 2024 //
GLOBENEWSWIRE
Supernus Announces First Quarter 2024 Financial Results
08 May 2024 //
GLOBENEWSWIRE
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
01 May 2024 //
GLOBENEWSWIRE
Supernus Pharma to Report Q1 2024 Results on May 8
24 Apr 2024 //
GLOBENEWSWIRE
US FDA declines to approve Supernus` Parkinson`s combination again
09 Apr 2024 //
REUTERS
Supernus Provides Regulatory Update for SPN-830
08 Apr 2024 //
GLOBENEWSWIRE
Supernus to Participate in Two Upcoming Investor Conferences
06 Mar 2024 //
GLOBENEWSWIRE
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
28 Feb 2024 //
GLOBENEWSWIRE
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Supernus to Announce Fourth Quarter and Full Year 2023 Financial Results
13 Feb 2024 //
GLOBENEWSWIRE
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
05 Feb 2024 //
GLOBENEWSWIRE
Supernus Announces Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Supernus to Participate in the Jefferies London Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review
02 Nov 2023 //
GLOBENEWSWIRE
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
Jay Glazer Teams Up with Supernus Pharmaceuticals
16 Oct 2023 //
GLOBENEWSWIRE
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
09 Oct 2023 //
GLOBENEWSWIRE
Supernus Announces Webcast of R&D Day to be Held on October 18
27 Sep 2023 //
GLOBENEWSWIRE
Supernus to Participate in the Wells Fargo Healthcare Conference
31 Aug 2023 //
GLOBENEWSWIRE
Bethany L. Sensenig Joins Supernus™ Board of Directors
21 Aug 2023 //
GLOBENEWSWIRE
Supernus Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results
24 Jul 2023 //
GLOBENEWSWIRE
Supernus to Participate in the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Supernus Announces First Quarter 2023 Financial Results
09 May 2023 //
GLOBENEWSWIRE
Supernus to Present at the Bank of America 2023 Health Care Conference
02 May 2023 //
GLOBENEWSWIRE
Supernus to Announce 1Q 2023 FYR and Host Conference Call on May 9, 2023
25 Apr 2023 //
GLOBENEWSWIRE
Supernus Announces Repayment of Convertible Notes
03 Apr 2023 //
GLOBENEWSWIRE
Supernus to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Working its way through a CRL on lead drug, Supernus taps $150M loan
15 Feb 2023 //
ENDPTS
Supernus Enters Into $150 Million Credit Facility
14 Feb 2023 //
GLOBENEWSWIRE
Supernus to Announce Fourth Quarter and Full Year 2022 Financial Results
09 Feb 2023 //
GLOBENEWSWIRE
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Supernus to Present at Two November Healthcare Conferences
08 Nov 2022 //
GLOBENEWSWIRE
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results
25 Oct 2022 //
GLOBENEWSWIRE
FDA rejects Supernus’ drug infusion device for Parkinson’s
11 Oct 2022 //
BIOPHARMADIVE
Supernus Provides Regulatory Update on SPN-830
10 Oct 2022 //
GLOBENEWSWIRE
Supernus Announces Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results
25 Jul 2022 //
GLOBENEWSWIRE
Supernus to Participate in the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Supernus Announces First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults
29 Apr 2022 //
GLOBENEWSWIRE
Supernus Reports Final Audited Q4 and Full Year 2021 Financial Results
13 Apr 2022 //
GLOBENEWSWIRE
